Metabolic Positron Emission Tomography in Breast Cancer.

Authors :: Cecil K
Huppert L
Mukhtar R
Dibble EH
O'Brien SR
Ulaner GA
Lawhn-Heath C
Source :: PET clinics [PET Clin] 2023 Oct; Vol. 18 (4), pp. 473-485. Date of Electronic Publication: 2023 Jun 25.
Publication Year :: 2023
Abstract: Metabolic PET, most commonly 18F-fluorodeoxyglucose (FDG) PET/computed tomography (CT), has had a major impact on the imaging of breast cancer and can have important clinical applications in appropriate patients. While limited for screening, FDG PET/CT outperforms conventional imaging in locally advanced breast cancer. FDG PET/CT is more sensitive than conventional imaging in assessing treatment response, accurately predicting complete response or nonresponse in early-stage cases. It also aids in determining disease extent and treatment response in the metastatic setting. Further research, including randomized controlled trials with FDG and other metabolic agents such as fluciclovine, is needed for optimal breast cancer imaging.<br /> (Copyright © 2023 Elsevier Inc. All rights reserved.)